Table 4. Association between immunosuppression and BKPyVAN.
| Hazard ratio (Exp B) | 95% CI | P value | ||
|---|---|---|---|---|
| Crude model | 3.378 | 1.075 | 10.61 | 0.037 |
| Model 1 | 4.286 | 1.307 | 14.05 | 0.016 |
| Model 2 | 3.636 | 1.125 | 11.750 | 0.031 |
| Model 3 | 3.365 | 1.067 | 10.609 | 0.038 |
| Model 4 | 3.428 | 1.083 | 10.849 | 0.036 |
| * Crude model | 3.741 | 1.190 | 11.762 | 0.024 |
| Model 5 | 3.897 | 1.223 | 12.413 | 0.021 |
Cox regression was used for multivariate analysis of proven BKPyVAN during 24 months, between the treatment arm TacM vs. CsAM (reference). Model 1: adjusted for type of donor (Living vs. deceased), cold ischemia time and BPAR. Model 2: adjusted for HLA mismatch (AB, DR). Model 3: adjusted for primary disease. Model 4: adjusted for recipient sex and age. Model 5: adjusted for donor sex and age.
* The crude model of model 5 differs from the other models in the number of missing cases.